Drugs Containing Excipient (Inactive Ingredient) SOYBEAN OIL

Branded drugs containing SOYBEAN OIL excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	LAMPRENE	clofazimine	0078-1049	SOYBEAN OIL
Chiesi USA Inc	CLEVIPREX	clevipidine	10122-610	SOYBEAN OIL	2031-10-10
Chiesi USA Inc	CLEVIPREX	clevipidine	10122-611	SOYBEAN OIL	2031-10-10

Generic drugs containing SOYBEAN OIL excipient

Company	Ingredient	NDC	Excipient
Pfizer Laboratories Div Pfizer Inc	propofol	0069-0209	SOYBEAN OIL
Novartis Pharmaceuticals Corporation	clofazimine	0078-1049	SOYBEAN OIL
L Perrigo Company	ibuprofen	0113-0788	SOYBEAN OIL

Soybean Oil Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: August 3, 2026

Soybean oil is a low-cost, multifunctional pharmaceutical excipient used in parenteral lipid emulsions, oral softgels, topical products and selected drug-delivery systems. Its pharmaceutical value is driven less by the intrinsic oil price than by purification, oxidation control, traceability, sterility assurance and regulatory documentation.

The market has a favorable volume outlook but limited pricing power. Pharmaceutical demand is small relative to food, feed and biofuel consumption, so commodity soybean-oil prices remain the primary cost variable. The strongest commercial opportunities are in high-purity grades, injectable emulsions, lipid-based formulations and supply contracts that require validated quality systems.

What is pharmaceutical-grade soybean oil used for?

Pharmaceutical-grade soybean oil is a refined vegetable oil used as an excipient, solvent, emollient and lipid-phase carrier. Its principal applications are:

Application	Function of soybean oil	Commercial relevance
Intravenous lipid emulsions	Caloric source and lipid carrier	High regulatory and quality barriers
Propofol emulsions	Oil phase for drug solubilization	Established generic and branded use
Oral softgels	Carrier for lipophilic APIs	Large formulation base
Nutraceutical and pharmaceutical capsules	Solvent and vehicle	Volume-oriented, lower margin
Topical and dermatological products	Emollient and dispersing agent	Fragmented demand
Lipid-based drug delivery	Solubilizer and absorption enhancer	Growth opportunity
Veterinary formulations	Carrier and nutritional lipid	Secondary pharmaceutical market

The excipient is generally supplied as highly refined soybean oil with controlled acid value, peroxide value, water content, impurities, residual solvents and microbial quality. Injectable products require tighter controls than oral and topical grades.

The United States Pharmacopeia-National Formulary includes a monograph for Soybean Oil. FDA’s Inactive Ingredient Database also identifies soybean oil in approved drug products and dosage forms, although database entries do not establish that every product uses the same supplier or grade.[1,2]

How large is the soybean oil pharmaceutical excipient market?

A standalone global market figure for pharmaceutical-grade soybean oil is not publicly reported with consistent definitions. Most commercial market reports aggregate soybean oil across food, industrial, cosmetic, nutraceutical and pharmaceutical applications.

The pharmaceutical segment is small compared with total soybean-oil consumption. Its economic importance comes from qualification requirements rather than scale. Pharmaceutical buyers typically pay for:

• Controlled refining and filtration
• Low peroxide and anisidine values
• Batch-to-batch consistency
• Compliance with USP-NF, Ph. Eur. or equivalent standards
• Allergen and identity documentation
• Residual solvent and elemental impurity controls
• Change-control commitments
• Auditable manufacturing records
• Long-term supply continuity

Revenue exposure for dedicated excipient suppliers is difficult to isolate because companies generally report plant oils within broader pharmaceutical ingredients, specialty chemicals, nutrition or personal-care segments. Public companies such as Archer Daniels Midland, Bunge and Cargill have far greater exposure to commodity oilseeds and food ingredients than to pharmaceutical excipients.[3,4]

The commercial implication is clear: soybean oil is a high-volume commodity input but a niche pharmaceutical product when measured by qualified grade and application.

What factors are driving soybean oil excipient demand?

Growth in lipid-based formulations

Lipid-based drug delivery remains the main technical growth driver. Soybean oil can dissolve or disperse poorly water-soluble active ingredients and can support oral, injectable and topical dosage forms.

Demand is strongest where the formulation requires a biologically acceptable oil with established regulatory use. Developers often prefer an excipient with a long history in marketed products because excipient novelty can increase regulatory review and formulation risk.

Parenteral nutrition and injectable emulsions

Soybean oil is a principal lipid source in several intravenous lipid emulsions. Intralipid, marketed by Fresenius Kabi, contains soybean oil with egg phospholipids, glycerin and water for injection. Comparable lipid emulsions and parenteral nutrition products create recurring demand for high-quality soybean oil.[5]

Injectable use is strategically important because it creates higher switching costs. A supplier change can trigger comparability work, stability testing, process validation and regulatory filing updates.

Propofol and other emulsion products

Propofol injectable emulsions use an oil-in-water emulsion system that commonly includes soybean oil and egg lecithin. The product category has a broad generic base and recurring hospital demand. Soybean oil demand therefore benefits from procedure volumes, intensive-care utilization and anesthesia-product supply contracts.

This segment also demonstrates the limits of pharmaceutical excipient pricing. Generic competition places pressure on finished-product manufacturers, which in turn encourages cost control across excipient procurement.

Softgel and oral dosage-form demand

Soybean oil is established in softgel formulations for lipophilic drugs, vitamins and supplements. This is a larger potential volume market than injectable use, but margins are usually lower because multiple edible, nutraceutical and pharmaceutical oils can compete as formulation carriers.

Substitution candidates include corn oil, sesame oil, medium-chain triglycerides, mineral oil, olive oil and synthetic lipid excipients. The selected substitute depends on solubility, oxidation stability, capsule compatibility, sensory profile and regulatory history.

How do commodity prices affect pharmaceutical soybean oil economics?

Commodity soybean-oil pricing is influenced by soybean production, crushing margins, global inventories, edible-oil demand, export flows and biofuel policy. Renewable diesel and biodiesel demand are particularly important because they can redirect soybean oil into fuel markets and tighten availability for other uses.[6,7]

The cost structure has two distinct layers:

Cost layer	Main drivers	Effect on pharmaceutical suppliers
Crude or refined soybean oil	Crop yields, crush economics, biofuel demand	High volatility
Pharmaceutical conversion	Purification, filtration, testing, packaging and documentation	Higher stability and margin

Pharmaceutical-grade suppliers can pass through some raw-material inflation, but their ability to raise prices is constrained by:

• The availability of alternative vegetable oils
• Generic-drug procurement pressure
• Long-term customer contracts
• Customer qualification of multiple suppliers
• The small share of soybean oil in the total cost of many finished medicines

A major exception is sterile or injectable-grade supply. In that segment, the cost of qualification and the risk of supply interruption can support better pricing than the raw commodity would suggest.

What is the financial trajectory for pharmaceutical soybean oil?

The financial trajectory is likely to divide into three segments.

Base case: steady volume growth and moderate value growth

The base case is for steady demand growth tied to parenteral nutrition, injectable emulsions, softgels and lipid-based formulation development. Revenue growth should be moderate rather than high because soybean oil is a mature excipient with extensive substitution options.

Value growth can exceed volume growth when buyers shift from basic refined oil to documented pharmaceutical grades with tighter oxidation, impurity and microbiological controls.

Upside case: stronger growth from injectable and advanced lipid systems

The upside case depends on expanded use in:

• Complex injectable emulsions
• Lipid nanoparticles and related delivery platforms
• High-load oral formulations for poorly soluble APIs
• Specialty nutrition products
• Outsourced pharmaceutical manufacturing

The strongest upside would come from applications in which the excipient is embedded in a validated formulation and is difficult to replace without new stability and regulatory work.

Downside case: substitution and biofuel-driven input inflation

The downside case combines high soybean-oil prices with substitution by medium-chain triglycerides, synthetic lipids or other vegetable oils. Biofuel demand can raise the input cost without increasing pharmaceutical pricing proportionately.

Finished-dose manufacturers with low-margin generic products are the most exposed. Suppliers with diversified oil portfolios, regional inventory and validated alternate sources are better positioned.

Which companies supply pharmaceutical-grade soybean oil?

The supply chain includes integrated agricultural processors, specialty excipient manufacturers, contract refiners and distributors. Relevant company groups include:

Supplier category	Representative companies	Competitive position
Integrated oilseed processors	ADM, Bunge, Cargill	Scale, feedstock access and global logistics
Specialty excipient manufacturers	Croda and other high-purity excipient producers	Documentation, purification and regulatory support
Oleochemical suppliers	Regional refined-lipid manufacturers	Custom grades and regional service
Distributors	Spectrum Chemical, Merck/Sigma-Aldrich and specialty distributors	Small-batch access and laboratory supply
Contract manufacturers	Pharmaceutical formulators and parenteral-product producers	Captive or qualified supply arrangements

The competitive landscape is fragmented at the pharmaceutical-grade level. Agricultural scale does not automatically translate into injectable-excipient qualification. Pharmaceutical customers prioritize validated processing, change-control discipline and documentation over lowest raw-material cost.

What regulatory status applies to soybean oil as an excipient?

Soybean oil is an established excipient in the United States and Europe, but regulatory status depends on grade, route of administration and finished-product formulation.

United States

FDA recognizes soybean oil through its use in approved products and its listing in the Inactive Ingredient Database. The database supports regulatory precedent but does not eliminate the need for product-specific quality, safety and formulation documentation.[2]

For injectable use, manufacturers must address:

• Sterility and endotoxin controls
• Oxidative degradation
• Particle-size and emulsion stability
• Extractables and leachables
• Container-closure compatibility
• Manufacturing process controls
• Allergen-related labeling and risk assessment

Soybean-derived components can raise sensitivity and allergen questions. The risk assessment applies to the finished product and manufacturing process, not merely to the chemical identity of the oil.

Europe and other jurisdictions

European pharmaceutical manufacturers typically rely on Ph. Eur. standards, supplier qualification and the excipient information expected under EU good manufacturing practice requirements. Multinational suppliers often maintain USP-NF and Ph. Eur.-aligned documentation to avoid separate supply chains.

There is no biosimilar pathway for soybean oil. It is a small-molecule excipient, not a biologic. Paragraph IV certification, Orange Book listing and generic patent certification apply to drug products, not to the excipient as a standalone material.

What patents protect pharmaceutical soybean oil formulations?

Soybean oil itself is generally a weak patent subject because the material is a known natural product with extensive prior art. Commercial protection usually resides in the finished dosage form or manufacturing process.

Potentially protectable subject matter includes:

• Specific oil-in-water emulsion compositions
• Defined oil-to-surfactant ratios
• Particle-size distributions
• Stabilization systems
• Sterilization and filling processes
• Novel combinations with active ingredients
• Controlled-release lipid matrices
• Improved physical stability
• Reduced injection-site reactions
• Manufacturing methods that improve shelf life

The relevant patent holder is usually the drug manufacturer, not the soybean-oil supplier. Orange Book-listed patents may cover a finished drug’s formulation or method of use, but they do not create broad exclusivity over pharmaceutical soybean oil.

Patent strength is therefore application-specific:

Asset	Typical patent strength
Soybean oil as a general excipient	Low
Purity specification alone	Low to moderate
Novel emulsion architecture	Moderate to strong
Drug-specific lipid formulation	Moderate to strong
Manufacturing process with measurable advantage	Moderate
Supplier purification process	Variable and often trade-secret dependent

Trade secrets, supplier qualification and process know-how can be more commercially important than patents for high-purity grades.

What litigation and licensing risks affect the market?

No broad patent litigation trend targets soybean oil as a pharmaceutical excipient. Disputes are more likely to arise in finished products, including injectable emulsions, softgels and lipid-based drug-delivery systems.

The principal legal and commercial risks are:

1. Finished-drug formulation patents that restrict generic substitution.
2. Supplier agreements containing exclusivity, territory or minimum-volume provisions.
3. Quality disputes involving oxidation, contamination or specification failure.
4. Change-control disputes after feedstock, processing or manufacturing-site changes.
5. Product-liability claims involving hypersensitivity or administration reactions.
6. Regulatory disputes over excipient documentation and manufacturing controls.

Licensing deals generally concern the drug formulation, delivery platform or manufacturing process. They rarely license soybean oil itself because multiple producers can supply comparable material after qualification.

Which geographic markets have the strongest prospects?

North America and Europe remain the most attractive markets for high-documentation pharmaceutical grades because of large generic, injectable and specialty-pharmaceutical manufacturing bases.

Asia-Pacific has the strongest volume potential due to:

• Expansion of generic-drug manufacturing
• Growth in parenteral nutrition
• Increasing softgel production
• Local pharmaceutical outsourcing
• Rising demand for documented excipients

China and India also present price competition and qualification complexity. Local manufacturers can offer lower-cost material, while multinational drug companies may require dual sourcing, audited facilities and globally aligned quality systems.

Geographic supply risk is concentrated in the agricultural and refining stages. Regional crop failures, export restrictions, port disruptions and biofuel policy changes can affect global pricing even when pharmaceutical demand is stable.

What generic-entry risks exist for soybean-oil-containing drugs?

Generic entry risk depends on the finished product, not on the excipient.

For established products such as propofol emulsions and parenteral nutrition products, generic competition is already significant. New entrants must demonstrate pharmaceutical equivalence, emulsion characteristics, stability and manufacturing quality. Soybean oil does not normally create a standalone barrier, but a proprietary emulsion system may complicate equivalence testing.

For softgels, generic entry is usually easier when the active ingredient has straightforward bioequivalence requirements. Formulations with complex lipid absorption behavior can create greater development risk.

The commercial risk to soybean-oil suppliers is moderate. Generic entry can reduce finished-drug prices, but it can also expand total excipient consumption by increasing product volumes and the number of qualified manufacturers.

Key Takeaways

• Soybean oil is an established pharmaceutical excipient with applications in injectable emulsions, propofol, parenteral nutrition, softgels and topical products.
• Pharmaceutical demand is small relative to food, feed and biofuel markets.
• Commodity pricing is controlled by soybean production, crushing economics and biofuel demand.
• Pharmaceutical-grade suppliers earn value through purification, documentation, quality control and supply reliability.
• Injectable and complex lipid formulations provide the best margin and switching-cost profile.
• Soybean oil itself has limited patent strength; exclusivity usually resides in finished-product formulations or manufacturing processes.
• Paragraph IV, Orange Book and biosimilar issues apply to drug products, not to soybean oil as a standalone excipient.
• The base-case financial outlook is steady volume growth with moderate value growth.
• The principal downside risks are raw-material inflation, excipient substitution and generic-drug procurement pressure.
• No reliable standalone public revenue figure exists for pharmaceutical-grade soybean oil; supplier exposure is generally embedded in broader ingredient businesses.

FAQs

Is soybean oil an FDA-approved pharmaceutical excipient?

Soybean oil is an established excipient in FDA-approved drug products and is listed in FDA’s Inactive Ingredient Database. Its acceptability still depends on route, grade, manufacturing controls and the finished formulation.[2]

Is pharmaceutical soybean oil different from food-grade soybean oil?

Yes. Pharmaceutical grades require tighter specifications, controlled processing, batch documentation, impurity testing and supplier qualification. Injectable grades require additional controls for sterility-related manufacturing and emulsion performance.

Can soybean oil be replaced by medium-chain triglycerides?

In some formulations, yes. Replacement requires evaluation of solubility, oxidation stability, absorption, emulsion behavior, compatibility and regulatory documentation. A supplier change may require stability and regulatory work.

Does soybean oil create an allergen risk in injectable medicines?

It can create a product-specific allergen and labeling assessment. The risk depends on refining, residual proteins, manufacturing controls and the clinical route of administration.

Are pharmaceutical soybean-oil suppliers exposed to biodiesel demand?

Yes. Biodiesel and renewable diesel can increase competition for soybean oil feedstock and raise input costs. The effect is transmitted through the commodity market, even though pharmaceutical demand is comparatively small.

References

1. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Soybean Oil monograph. USP-NF.
2. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
3. Archer Daniels Midland Company. (2024). Annual report 2023.
4. Bunge Global SA. (2024). Annual report 2023.
5. Fresenius Kabi USA. (2024). Intralipid prescribing information.
6. U.S. Department of Agriculture, Foreign Agricultural Service. (2024). Oilseeds: World markets and trade.
7. U.S. Energy Information Administration. (2024). Biofuels and renewable diesel market data.